October 04, 2019
1 min read

Experts discuss Zantac recall, Cologuard approved for younger age range – top stories in gastroenterology

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In a Q&A with Healio, gastroenterologists shared how they are handling the recent Zantac recalls in their practices, and Cologuard — a noninvasive colorectal cancer screening test — received FDA approval for at-risk individuals aged 45 years or older.

These and more were the most popular stories in gastroenterology last week.

Q&A: How three gastroenterologists are handling the Zantac recall

To gauge how gastroenterologists are approaching the evolving landscape involving Zantac, Healio reached out to several physicians about the initial distribution halt and subsequent voluntary recall. Read more.

Cologuard approved for adults aged 45 and older

Cologuard, a non-invasive colorectal cancer screening test, has been approved for use in at-risk patients aged 45 and older. Read more.

Q&A: VARSITY, UNIFI add to the armamentarium for ulcerative colitis

Physicians have an array of biologic agents available to treat patients with ulcerative colitis, but it is still unknown which therapies are superior, as well as which therapies work best in certain instances. Read more.

American Gastroenterological Association issues new chronic diarrhea guidelines

The American Gastroenterological Association released new clinical practice guidelines for the evaluation of chronic diarrhea. Read more.

No increase in mortality rate before, after colonoscopy screening

Despite an increase in unplanned hospitalizations, colonoscopy is not associated with any increase in mortality as a colorectal cancer screening intervention, according to study results. Read more.